HONG KONG – China-based ophthalmology startup Ocumension Therapeutics Ltd. has inked a deal for potentially €36.25 million (US$41.35 million) to develop and commercialize French counterpart Nicox SA's NCX-470 in the Chinese mainland, Hong Kong, Macau and Taiwan. NCX-470 is a monoclonal antibody (MAb) for treating open-angle glaucoma and ocular hypertension.